An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension.

In the pilot study, five PAH patients on background therapy were administered a single IV dose of GSK2586881 (three at 0.2 mg/kg and two at 0.4 mg/kg), which demonstrated a significant trend for an increase in cardiac output and a reduction in PVR (between 1 and 4 h postdose). 23 Increased RAS pathway activation is associated with pulmonary vascular dysfunction.

also in 9,775 other papers